A faster detection method for high-sensitivity cardiac troponin—POCT quantum dot fluorescence immunoassay

Acute myocardial infarction (AMI) is one of the major diseases that threaten human health. In recent years, the incidence of AMI has been increasing year by year (1-3). The early diagnosis of AMI is conducive to rapid diagnosis and treatment which can improve the prognosis of patients with AMI (4,5). High-sensitivity cardiac troponin (hs-cTn) can measure even low cTn concentration with high precision, which has important clinical significance for the diagnosis and risk stratification of AMI, and is a specific indicator for the diagnosis of AMI (2,6,7,8). According to the guidelines, if the results of hs-cTn did not increase in patients with chest pain at admission, blood sample should be taken again at intervals of 1 to 2 hours, and compared with the first results, if the results increased by more than 30%, the diagnosis of AMI should be considered (2,9). In addition, it has been shown that elevated troponin is associated with an increased risk of adverse outcome in patients with AMI (10). However, electrochemiluminescence is most commonly used to detect troponin at present. The method is currently detected on a large biochemical analyzer, and the time taken to detect hs-cTn is long, which means that it, s unable to perform bedside inspection and count against the rapid diagnosis of AMI (11-13). While the disadvantage of traditional Point of Care Testing (POCT) method is using serum, which is not possible at pre-hospital first aid. Therefore, the research of POCT quantum dot immunofluorescence based on whole blood is more valuable